FDA Approves Qternmet XR, New Type 2 Diabetes Combo Pill

The U.S. Food and Drug Administration (FDA) has approved Qternmet XR extended-release tablets as an adjunct treatment to diet and exercise in adults with type 2 diabetes. According to a press release from manufacturer AstraZeneca, the oral medicine is a combination of the SGLT2 inhibitor dapagliflozin, the DPP-4 inhibitor saxagliptin and metformin extended-release.


The approval was based on the results of two phase 3 trials evaluating different combinations of dapagliflozin and saxagliptin on a base of metformin over 24 weeks.

Want to learn more about SGLT2 inhibitors, DPP-4 inhibitors and metformin? Read “Diabetes Medicine: SGLT2 Inhibitors,” “Diabetes Medicine: DPP-4 Inhibitors” and “What to Know About Metformin.”

Learn more about the health and medical experts who who provide you with the cutting-edge resources, tools, news, and more on Diabetes Self-Management.
About Our Experts >>